NCT04444050View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions
Healthy Participants
Interventions
DRUG

BMS-986331

Specified dose on specified days

OTHER

Placebo, Matching BMS-986331

Specified dose on specified days

Trial Locations (2)

66219

ICON (LPRA) - Lenexa, Lenexa

92801

Local Institution - 0001, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY